Skip to main content
. 2020 Apr 24;31(5):1128–1139. doi: 10.1681/ASN.2019111168

Figure 5.

Figure 5.

Canagliflozin reduced HbA1c, BP, body weight, and albuminuria compared with placebo in participants across screening eGFR subgroups. Data are placebo-subtracted mean difference (95% CI), except for UACR where it is percentage change in the geometric mean of canagliflozin relative to placebo.